Detalhe da pesquisa
1.
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis.
Cytokine
; 177: 156543, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38373365
2.
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis species.
Exp Parasitol
; 260: 108743, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513973
3.
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis.
Cytokine
; 164: 156143, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774730
4.
In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
Exp Parasitol
; 251: 108555, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247802
5.
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
Parasitol Res
; 122(12): 2917-2931, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768367
6.
Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.
Cytokine
; 153: 155865, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35339043
7.
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteins.
Microb Pathog
; 162: 105341, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883228
8.
Evaluation from a B-cell epitope-based chimeric protein for the serodiagnosis of tegumentary and visceral leishmaniasis.
Microb Pathog
; 167: 105562, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35513293
9.
Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.
Parasite Immunol
; 44(8): e12921, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35437797
10.
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection.
Parasitol Res
; 120(12): 4037-4047, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664113
11.
Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
Cytokine
; 129: 155031, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32062145
12.
Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells.
Parasitol Res
; 119(8): 2609-2622, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32535734
13.
Screening diagnostic candidates from Leishmania infantum proteins for human visceral leishmaniasis using an immunoproteomics approach.
Parasitology
; 146(11): 1467-1476, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142384
14.
A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
Cell Immunol
; 313: 32-42, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049560
15.
Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with Leishmania amazonensis.
Pathogens
; 12(2)2023 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36839586
16.
Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis.
Biology (Basel)
; 12(6)2023 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37372136
17.
The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice.
Acta Trop
; 246: 106986, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453579
18.
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.
Mol Immunol
; 155: 79-90, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36731193
19.
B-Cell Epitopes-Based Chimeric Protein from SARS-CoV-2 N and S Proteins Is Recognized by Specific Antibodies in Serum and Urine Samples from Patients.
Viruses
; 15(9)2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37766284
20.
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection.
Vaccines (Basel)
; 10(7)2022 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35891310